
FULC Stock Forecast & Price Target
FULC Analyst Ratings
Bulls say
Fulcrum Therapeutics Inc. has garnered increased enthusiasm for its pociredir program, particularly following the recent withdrawal of Oxbryta, which may enhance patient enrollment rates and rebuild trust within the community. The company has demonstrated resilience by successfully pivoting from a previous clinical hold and is now reporting promising early signs of clinical activity in its phase Ib study, including dose-dependent increases in fetal hemoglobin levels and improvements in biomarkers. Additionally, Fulcrum's commitment to maintaining a disciplined restructuring strategy and aligning with ESG principles positions it favorably for sustainable growth and value creation in the biopharmaceutical space.
Bears say
Fulcrum Therapeutics reports significant net losses, with $21.6 million in 3Q24 and $16.5 million in 4Q24, highlighting ongoing financial challenges. The clinical development of losmapimod has faced setbacks, including a failure to meet primary endpoints in the Phase III REACH trial, raising concerns about the efficacy of its lead product. Additionally, risks associated with the pociredir compound in clinical studies could further diminish the company's market value, potentially reducing its stock to a level that reflects only its net cash position.
This aggregate rating is based on analysts' research of Fulcrum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
FULC Analyst Forecast & Price Prediction
Start investing in FULC
Order type
Buy in
Order amount
Est. shares
0 shares